Citigroup
IMUC

Citigroup’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Citigroup’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-543
Closed -$3K – 7537
2016
Q3 		$3K Hold
543
– – ﹤0.01% 6908
2016
Q2 		$5K Sell
543
-15
-3% -$154 ﹤0.01% 6807
2016
Q1 		$6K Sell
558
-235
-30% -$2.64K ﹤0.01% 6978
2015
Q4 		$11K Buy
793
+250
+46% +$4.13K ﹤0.01% 6799
2015
Q3 		$9K Hold
543
– – ﹤0.01% 6524
2015
Q2 		$10K Hold
543
– – ﹤0.01% 6498
2015
Q1 		$11K Buy
543
+293
+117% +$7.36K ﹤0.01% 6445
2014
Q4 		$7K Buy
250
+110
+79% +$3.17K ﹤0.01% 6621
2014
Q3 		$5K Sell
140
-641
-82% -$24.7K ﹤0.01% 6617
2014
Q2 		$35K Buy
781
+656
+525% +$31.7K ﹤0.01% 5436
2014
Q1 		$6K Sell
125
-688
-85% -$33.6K ﹤0.01% 6577
2013
Q4 		$30K Buy
813
+574
+240% +$54.4K ﹤0.01% 5999
2013
Q3 		$24K Sell
239
-136
-36% -$14.9K ﹤0.01% 5820
2013
Q2 		$29K Buy
+375
New +$35.9K ﹤0.01% 5666

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Citigroup's IMUC Position: Q4 2016 in Review

Citigroup sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 543 shares — an estimated $3K sold.

Citigroup first reported a position in IMUC in Q2 2013 and held it in 14 quarters. The position peaked at $35K in Q2 2014. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

  • Citigroup reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
  • Citigroup sold 543 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016, an estimated $3K.
  • Citigroup first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 14 quarters.
  • Citigroup's ImmunoCellular Therapeutics, Ltd. position peaked at $35K in Q2 2014.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Citigroup's 13F filing for Q4 2016, filed 10 Feb 2017.